The quality of human (and veterinary) health care systems substantially depends on key innovations. Often, these were driven by the field of physics, followed by interdisciplinary and inter-sectorial actions in engineering, chemistry, biology, and medicine, such as X-rays in medical diagnostics, ionizing radiation in cancer treatment, and femtosecond lasers for precision surgery. Medical gas plasma technology was introduced to human health care a decade ago. Today, accredited medical plasma devices are in daily operation in dozen dermatology centers in middle Europe to improve wound healing. In addition, physical plasmas were shown to inactivate cancerous cells. Actinic Keratosis is a skin disease affecting millions of Europeans and making them prone to invasive and deadly skin cancer. Many of the available treatment options are associated with low efficacy, pain, risks, and/or high costs. Medical gas plasma technology is operated at body temperature and applied painlessly, cost-effectively, and without notable side effects. Gas plasma has been suggested to be active on high-grade cancer cells, but its activity against premalignant cells, as in Actinic Keratosis, is unknown. By using beyond state-of-the-art plasma multijet technology, the primary technical objective of PlasmACT – Plasma against Actinic Keratosis – is to support skin cancer prevention by medical gas plasma therapy of Actinic Keratosis. PlasmACT does so by educating a new generation of application-oriented scientists that are exposed to questions and findings from different scientific fields (interdisciplinary from physics over chemistry and biology to medicine) and capable of addressing questions in view of both academic as well as business needs (inter-sectoral) while incorporated in a vivid and productive environment across borders and cultures (international).

"In a recent publication, the Minister Eliane Tillieux, highlighted the importance of mental health and its management in a government policy. Following the Green Paper dedicated to mental health and drafted by the European Commission, many action plans were enacted with the current Belgian reform called ""107"",which is an outcome.Some alarming facts: stress and burnout become a leading cause of absenteeism at work, the behavior addictions reduce business productivity, suicide is one of the main mortality factors in our society which has a growing impact on life expectancy. 25% of the population claims to have fought against a psychic malaise.Facing these problems that are highly threatening the social cohesion and productivity, public policies and mental health actors are mobilized to solve these problems. In contrast to somatic medicine whose aspects are dominant technologies, working in mental health is based on the skills acquired by professional care and support.Facing these challenges, it is clear that academic training does not correspond to the fast changing evolution in the needs of the institutions. In that way, nurses, caregivers who are involved in the health sector, require additional training and one of the institution mission is to contribute at the development of its staff.The project aims to acquire a complementary European curriculum to the freshly engaged personnel in the partners That curriculum will allow them to have a better understand of their tasks in the institution.We wish to perform a test of this device for three years. We have established a network of European expertise composed of excellence centers in which the workers will go complete their training on formal and informal learning that cannot be learned from the academic training curriculum.In return, the professional form the Neuropsychiatric Centre St-Martin will be able to disseminate their knowledge to the different partners. The staff tends to hastily leave the career, which is a major cause of scarcity, by this device, we want to increase the attractiveness of the profession and support the retention of the staff in de health care institutionsAfter different round of testing, different contact are already initiated in this direction, it will be a specialized year in psychiatry and health care that is going to be built.We will suggest a European tutoring with a European tour through three centers of excellence to new workers from 2015.During these three years of experimentation, an evaluation of the device through the center of health research located in Luxembourg, which has a great expertise on the subject, will be lead.Throughout these three years, the device will be adjusted and corrections will be implemented.This project contributes to the recommendations made by the European Commission in Belgium about the employability of employees and its cross-border mobility.A long-term ambition is in addition to the initial training to provide to the professional, skills in innovative expertise that would be integrated into a flexible and specialty adapted to technological developments and mindset to ensure an optimal quality of care.The diffusion of these innovations in mental health facilities will be organized so that all can benefit from this expertise and these feedbacks."

CombiDiag DN aims to develop an AI-data-driven peripheral biomarker based combinatorial diagnostic protocol for early stages of Alzheimers disease (AD), a major form of dementia, and to train a new generation of fellows for this interdisciplinary field. Dementia, a devastating disease of older age, is the challenge of our lifetime and one of the Societal Challenges listed by the UN Sustainable Development Goals and Horizon Europe. CombiDiag responds to this challenge to establish a much-needed DN to carry out an integrated study of minimally invasive and cost-effective peripheral biomarkers, including body fluid markers from blood, urine and saliva, and digital markers from speech, motor functions and sleep for developing the combinatorial early AD diagnostics. The consortium comprises nine academic and eight non-academic institutions across Europe, USA, Canada, and China. It synergises leading academic and industrial experts worldwide to build a triple-i research and training platform for the training of a new generation of Fellows to take early AD diagnostic research to a new level. Fellows will be trained under the Vitae Researcher Development Framework innovatively combined with the CombiDiag platform for triple-i scientific and transferable skills as well as personal quality, creative thinking, and business mind-set. The DN has a highly innovative research programme for the discovery of peripheral AD biomarkers, detection techniques, AI/data driven technology, clinical validation, and integration into trial designs. The advances in CombiDiag research will enable a case finding tool at primary care level for helping achieve improved drug discoveries, disease-modifying treatments, preventive strategies and care provision for AD. CombiDiag will deliver 10 highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.